Bigeye Revenue and Competitors
Estimated Revenue & Valuation
- Bigeye's estimated annual revenue is currently $8.4M per year.
- Bigeye's estimated revenue per employee is $134,710
- Bigeye's total funding is $71M.
Employee Data
- Bigeye has 62 Employees.
- Bigeye grew their employee count by 9% last year.
Bigeye's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Co-Founder, CEO | Reveal Email/Phone |
3 | Co-founder and CTO | Reveal Email/Phone |
4 | VP Modeling and Analytics | Reveal Email/Phone |
5 | Director Engineering | Reveal Email/Phone |
6 | Director Product Management | Reveal Email/Phone |
7 | Director Partnerships | Reveal Email/Phone |
8 | Director, Sales Engineering and Customer Success | Reveal Email/Phone |
9 | Chief Operating Officer | Reveal Email/Phone |
10 | Product Manager | Reveal Email/Phone |
Bigeye Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $88.7M | 499 | 32% | $240M | $1.6B |
#2 | $5.4M | 32 | -9% | $31M | N/A |
What Is Bigeye?
$71M
Total Funding
62
Number of Employees
$8.4M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Bigeye News
2022-04-17 - Ben Whiteman's big eye opener as a Preston North End player came against
Blackpool
Ben Whiteman's big eye opener as a Preston North End player came against Blackpool. The Preston North End midfielder is enjoying life under Ryan...
2022-04-06 - Papua New Guinea's Fishing Industry Association releases ...
... Council-certified yellowfin, skipjack, and bigeye tuna in 2021, according to its annual sustainability report, released in April 2022.
2022-03-30 - Hunting for next big eye disease drug, Regeneron gets ...
Hunting for next big eye disease drug, Regeneron gets deeper into gene therapies with ViGeneron pact. By Nick Paul Taylor Apr 6,...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.3M | 62 | -26% | N/A |
#2 | $8.1M | 62 | 38% | N/A |
#3 | $8.1M | 62 | -2% | N/A |
#4 | $3.5M | 62 | -2% | N/A |
#5 | $15.6M | 62 | 9% | N/A |